OXFORD, English, January 12, 2012 /PRNewswire/ --
PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi - Covance deal which won Scrip's 'Outsourcing Deal of the Year 2011'.
The judges described the deal as 'impressive' as it was "one the largest and most comprehensive R&D alliances in the history of the pharmaceutical and CRO industry".Under the terms of the agreement, Sanofi retains access to some of the capabilities that were divested to Covance as part of a long-term strategic alliance. Covance will provide Sanofi with an up to 10-year sole source relationship for central lab services.
Kevin Bottomley, Head of Transactions at PharmaVentures who was lead advisor to Sanofi on the deal said: "This is a great recognition for Sanofi as this was a ground-breaking deal which ultimately supports both its overall strategic intent."
Fintan Walton, Chief Executive of PharmaVentures said: "Deal making has become both more complex and more sophisticated. This Scrip Award recognises how PharmaVentures' clients are reaching new heights in deal making. We are delighted to be advisors to this award winning deal."
Over the years PharmaVentures has built considerable experience in the M&A field including divestments of manufacturing and R&D businesses.
Note to Editors
If you wish to write an article, please contact us for any further information you require.
PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabili
|SOURCE PharmaVentures Ltd|
Copyright©2010 PR Newswire.
All rights reserved